Stealth secured a new agency review of its experimental therapy elamipretide after a rejection this year. The result could ...

In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior ...

Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn ...

Faster review times could leave drugmakers vulnerable to litigation, while new Trump administration priorities add more ...

Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which ...

The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad.

Miguel Fernández Alcalde, head of Merck KGaA’s U.S. arm, aims to “double down” on innovation. The company’s recent SpringWorks deal is just a start.

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...